Dianthus Targets 2028 Data for Claseprubart Myasthenia Gravis Trial

Dianthus Pharmaceuticals is positioning its lead candidate, claseprubart, as a treatment for neuromuscular disorders. The company holds $1.2 billion in cash, which extends its operational runway through 2030. The firm is currently advancing its Phase III EMERGE study for myasthenia gravis (MG), with top-line data anticipated in the second half of 2028.

Clinical Differentiation and Speed of Efficacy

Management is highlighting the drug's rapid onset of action as a primary competitive advantage. In clinical settings, the company reports statistically significant improvements in patient outcomes within one week of administration.

"You guys should emphasize how fast this works. The stat sig separation on QMG and MG-ADL within seven days is also really impressive and important for MG patients and neurologists, and a key differentiator," said Marino Garcia, CEO of Dianthus, during the Citi summit.

These metrics, specifically the Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, serve as standardized tools to measure muscle weakness and functional impairment in patients.

Commercial Strategy and Administration

Beyond clinical speed, Dianthus is modeling its commercial launch strategy on existing biologics. The company aims to combine the safety profile of Sanofi’s ENJAYMO (sutimlimab) with the delivery convenience of Regeneron’s DUPIXENT, targeting a once-monthly dosing schedule via an autoinjector.

"If you can imagine a label for a product like claseprubart, where you just take the safety and tolerability from ENJAYMO, sutimlimab, which is approved in the U.S. for cold agglutinin disease, just cut and paste that safety label, put it on ours. And then go to the dosing administration for DUPIXENT, but make it once a month. The exact same autoinjector. That is what we are going to be launching with," said Garcia.

Expansion Into CIDP

In addition to the MG pipeline, the company is evaluating claseprubart for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Data from Part A of the CAPTIVATE trial suggests that the candidate may offer superior outcomes compared to standard intravenous immunoglobulin (IVIG) therapy.

"Three-quarters of patients are doing even better on claseprubart than they were doing on IVIG. That was information we didn't know before this year. That's clearly what we're seeing in Part A of our CAPTIVATE trial," Garcia noted.

For patients with CIDP, IVIG is a traditional treatment that typically requires frequent, hours-long infusions at clinical sites. An autoinjector-based therapy could shift the care model toward self-administration, reducing the logistical requirements for patients.